QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

BBIOTICKER

Bridgebio Pharma, Inc.

INSUFFICIENT DATA stock

Congress has disclosed 7 buys and 1 sell of BBIO (Bridgebio Pharma, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

7
Buy
1
Sell
+6
Net
1
Active politicians

Round-trip watch Still on the books

Members who disclosed buying BBIO and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Gilbert Cisneros 2026-05-11 $64.68 $74.95 +15.9% in profit

Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Legislation Related Legislation

Recent bills in this stock's sector (). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.

BillTitlePolicy areaLatest action
HR 10887 Protecting Consumer Access to Generic Drugs Act of 2026 Health 2026-10-22
HR 10874 Medicare Low Income Subsidy Equality Act of 2026 Health 2026-10-22
HR 10858 CARE for Blood Cancer Act of 2026 Health 2026-10-22
HR 10810 National Patient Safety Board Act of 2026 Health 2026-10-15
HR 10824 Stroke Education and EMS Care Improvement Act of 2026 Health 2026-10-15

8 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Gilbert Cisneros House SELL ◆ insider convergence Self · 150 Main Street Trust > Bank of America 2026-09-29 10 days -0.9% $1K–$15K
0.1% of NW
58.8 ↗ filing
Gilbert Cisneros House BUY ◆ insider divergence Self · 150 Main Street Trust > Bank of America 2026-05-11 25 days +4.5% $1K–$15K
0.1% of NW
6.2 ↗ filing
Gilbert Cisneros House BUY ◆ insider divergence Self · 150 Main Street Trust > Bank of America 2026-04-29 8 days -4.9% $1K–$15K
0.1% of NW
7.3 ↗ filing
Gilbert Cisneros House BUY ◆ insider divergence Self · 150 Main Street Trust > Bank of America 2026-03-19 18 days +3.2% $1K–$15K
0.1% of NW
7.3 ↗ filing
Gilbert Cisneros House BUY ◆ insider divergence Self · 150 Main Street Trust > Bank of America 2026-03-18 19 days +3.1% $1K–$15K
0.1% of NW
9.6 ↗ filing
Gilbert Cisneros House BUY ◆ insider divergence Self · 150 Main Street Trust > Bank of America 2026-03-03 34 days +12.0% $1K–$15K
0.1% of NW
17.1 ↗ filing
Gilbert Cisneros House BUY ◆ insider divergence · moderate Self · 150 Main Street Trust > Bank of America 2025-09-22 16 days +7.3% $1K–$15K
0.1% of NW
27.4 ↗ filing
Gilbert Cisneros House BUY ◆ insider divergence · moderate Self · 150 Main Street Trust > Bank of America 2025-08-08 31 days +16.6% $1K–$15K
0.1% of NW
63.1 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in BBIO — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

1
Congress trades with insider convergence
7
…with insider divergence
264
Insider open-market trades

Of the congressional trades in BBIO, 1 coincided with corporate insiders moving the same way within 60 days, and 7 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-10-30 Apuli Maricel C-suite SELL 10b5-1 $146K ↗ EDGAR
2026-09-17 Kumar Neil C-suite SELL 10b5-1 $602K ↗ EDGAR
2026-09-17 Kumar Neil C-suite SELL 10b5-1 $89K ↗ EDGAR
2026-08-19 Kumar Neil C-suite SELL 10b5-1 $679K ↗ EDGAR
2026-08-19 Kumar Neil C-suite SELL 10b5-1 $152K ↗ EDGAR
2026-08-19 Kumar Neil C-suite SELL 10b5-1 $9K ↗ EDGAR
2026-08-18 Kumar Neil C-suite SELL 10b5-1 $154K ↗ EDGAR
2026-08-18 Kumar Neil C-suite SELL 10b5-1 $1.4M ↗ EDGAR
2026-08-18 Kumar Neil C-suite SELL 10b5-1 $1.2M ↗ EDGAR
2026-08-18 Kumar Neil C-suite SELL 10b5-1 $100K ↗ EDGAR
2026-07-30 Apuli Maricel C-suite SELL 10b5-1 $160K ↗ EDGAR
2026-07-09 Cook Jennifer E. Director SELL 10b5-1 $3.0M ↗ EDGAR
2026-07-09 Cook Jennifer E. Director SELL 10b5-1 $10.1M ↗ EDGAR
2026-07-09 Ellis Andrea Director SELL 10b5-1 $1.4M ↗ EDGAR
2026-06-24 Cook Jennifer E. Director SELL 10b5-1 $2.6M ↗ EDGAR
2026-06-23 Valantine Hannah Director SELL 10b5-1 $151K ↗ EDGAR
2026-06-23 Cook Jennifer E. Director SELL 10b5-1 $151K ↗ EDGAR
2026-06-22 Valantine Hannah Director SELL 10b5-1 $191K ↗ EDGAR
2026-06-15 Cook Jennifer E. Director SELL 10b5-1 $5.9M ↗ EDGAR
2026-06-15 Cook Jennifer E. Director SELL 10b5-1 $101K ↗ EDGAR
2026-06-05 Kumar Neil C-suite SELL 10b5-1 $480K ↗ EDGAR
2026-06-05 Kumar Neil C-suite SELL 10b5-1 $573K ↗ EDGAR
2026-06-05 Kumar Neil C-suite SELL 10b5-1 $305K ↗ EDGAR
2026-06-05 Kumar Neil C-suite SELL 10b5-1 $480K ↗ EDGAR
2026-06-05 Kumar Neil C-suite SELL 10b5-1 $304K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2026-10-30 Apuli Maricel C-suite 10b5-1 SELL $146K
Congress 2026-09-29 Gilbert Cisneros SELL $1K–$15K
◆ insider 2026-09-17 Kumar Neil C-suite 10b5-1 SELL $602K
◆ insider 2026-09-17 Kumar Neil C-suite 10b5-1 SELL $89K
◆ insider 2026-08-19 Kumar Neil C-suite 10b5-1 SELL $679K
◆ insider 2026-08-19 Kumar Neil C-suite 10b5-1 SELL $152K
◆ insider 2026-08-19 Kumar Neil C-suite 10b5-1 SELL $9K
◆ insider 2026-08-18 Kumar Neil C-suite 10b5-1 SELL $154K
◆ insider 2026-08-18 Kumar Neil C-suite 10b5-1 SELL $1.4M
◆ insider 2026-08-18 Kumar Neil C-suite 10b5-1 SELL $1.2M
◆ insider 2026-08-18 Kumar Neil C-suite 10b5-1 SELL $100K
◆ insider 2026-07-30 Apuli Maricel C-suite 10b5-1 SELL $160K
◆ insider 2026-07-09 Cook Jennifer E. Director 10b5-1 SELL $3.0M
◆ insider 2026-07-09 Cook Jennifer E. Director 10b5-1 SELL $10.1M
◆ insider 2026-07-09 Ellis Andrea Director 10b5-1 SELL $1.4M
◆ insider 2026-06-24 Cook Jennifer E. Director 10b5-1 SELL $2.6M
◆ insider 2026-06-23 Valantine Hannah Director 10b5-1 SELL $151K
◆ insider 2026-06-23 Cook Jennifer E. Director 10b5-1 SELL $151K
◆ insider 2026-06-22 Valantine Hannah Director 10b5-1 SELL $191K
◆ insider 2026-06-15 Cook Jennifer E. Director 10b5-1 SELL $5.9M
◆ insider 2026-06-15 Cook Jennifer E. Director 10b5-1 SELL $101K
◆ insider 2026-06-05 Kumar Neil C-suite 10b5-1 SELL $480K
◆ insider 2026-06-05 Kumar Neil C-suite 10b5-1 SELL $573K
◆ insider 2026-06-05 Kumar Neil C-suite 10b5-1 SELL $305K

FAQ Common questions

How much has Congress traded BBIO?

7 disclosed buys and 1 sells of BBIO (Bridgebio Pharma, Inc.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade BBIO?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.